Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of September 4, 2026, TRDA trades at $7.12 with a market cap of $284.24M and a P/E ratio of -2.05. TRDA moved -0.70% today. Year to date, TRDA is -28.66%; over the trailing twelve months it is +37.36%. Its 52-week range spans $4.93 to $16.45. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
5 analysts cover TRDA: 0 strong buy, 4 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $17.00.
| Metric | Value |
|---|---|
| Price | $7.12 |
| Market Cap | $284.24M |
| P/E Ratio | -2.05 |
| EPS | $-3.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.45 |
| 52-Week Low | $4.93 |
| Volume | 206.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $25.42M |
| Net Income | $-143.75M |
| Gross Margin | 0.00% |
5 analysts cover TRDA: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.